Patient selection and CCT regimen

This is a retrospective cohort analysis of 171 consecutive patients with relapsed or refractory LBCL treated with standard of care axicabtagene ciloleucel (axi-cel) at our institution, The University of Texas MD Anderson Cancer Center (MDACC), between 01/2018 and 04/2020. Standard of care was defined as administration of commercial product outside of a clinical trial. Data cut-off was 04/2021. Patients received CCT with cyclophosphamide (500 mg/m²) and fludarabine (30 mg/m²) administered intravenously on days −5, −4 and −3, followed by axi-cel infusion (2 × 10⁶ cells/kg) on day 0. The study was approved by the Institutional Review Board of MD Anderson Cancer Center and conducted in accordance with our institutional guidelines and the principles of the Declaration of Helsinki.